Cell Biotech Statistics
Total Valuation
Cell Biotech has a market cap or net worth of KRW 92.67 billion. The enterprise value is 15.86 billion.
Market Cap | 92.67B |
Enterprise Value | 15.86B |
Important Dates
The last earnings date was Tuesday, November 12, 2024.
Earnings Date | Nov 12, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Cell Biotech has 6.84 million shares outstanding. The number of shares has decreased by -0.26% in one year.
Current Share Class | n/a |
Shares Outstanding | 6.84M |
Shares Change (YoY) | -0.26% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 34.46% |
Owned by Institutions (%) | 8.79% |
Float | 4.49M |
Valuation Ratios
The trailing PE ratio is 7.15.
PE Ratio | 7.15 |
Forward PE | n/a |
PS Ratio | 1.71 |
PB Ratio | 0.80 |
P/TBV Ratio | n/a |
P/FCF Ratio | 5.27 |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 1.36, with an EV/FCF ratio of 0.90.
EV / Earnings | 1.22 |
EV / Sales | 0.29 |
EV / EBITDA | 1.36 |
EV / EBIT | 2.06 |
EV / FCF | 0.90 |
Financial Position
The company has a current ratio of 14.55, with a Debt / Equity ratio of 0.01.
Current Ratio | 14.55 |
Quick Ratio | 13.73 |
Debt / Equity | 0.01 |
Debt / EBITDA | 0.11 |
Debt / FCF | 0.08 |
Interest Coverage | 104.90 |
Financial Efficiency
Return on equity (ROE) is 11.71% and return on invested capital (ROIC) is 4.35%.
Return on Equity (ROE) | 11.71% |
Return on Assets (ROA) | 4.12% |
Return on Capital (ROIC) | 4.35% |
Revenue Per Employee | 474.54M |
Profits Per Employee | 113.74M |
Employee Count | 114 |
Asset Turnover | 0.46 |
Inventory Turnover | 3.54 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +26.73% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | +26.73% |
50-Day Moving Average | 13,776.00 |
200-Day Moving Average | 12,996.10 |
Relative Strength Index (RSI) | 43.45 |
Average Volume (20 Days) | 20,136 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cell Biotech had revenue of KRW 54.10 billion and earned 12.97 billion in profits. Earnings per share was 1,893.42.
Revenue | 54.10B |
Gross Profit | 38.67B |
Operating Income | 7.78B |
Pretax Income | 14.14B |
Net Income | 12.97B |
EBITDA | 11.71B |
EBIT | 7.78B |
Earnings Per Share (EPS) | 1,893.42 |
Balance Sheet
The company has 78.14 billion in cash and 1.33 billion in debt, giving a net cash position of 76.81 billion or 11,223.01 per share.
Cash & Cash Equivalents | 78.14B |
Total Debt | 1.33B |
Net Cash | 76.81B |
Net Cash Per Share | 11,223.01 |
Equity (Book Value) | 115.82B |
Book Value Per Share | 16,922.86 |
Working Capital | 81.82B |
Cash Flow
In the last 12 months, operating cash flow was 18.31 billion and capital expenditures -734.47 million, giving a free cash flow of 17.57 billion.
Operating Cash Flow | 18.31B |
Capital Expenditures | -734.47M |
Free Cash Flow | 17.57B |
FCF Per Share | 2,567.93 |
Margins
Gross margin is 71.48%, with operating and profit margins of 14.38% and 23.97%.
Gross Margin | 71.48% |
Operating Margin | 14.38% |
Pretax Margin | 26.14% |
Profit Margin | 23.97% |
EBITDA Margin | 21.65% |
EBIT Margin | 14.38% |
FCF Margin | 32.49% |
Dividends & Yields
This stock pays an annual dividend of 450.00, which amounts to a dividend yield of 3.32%.
Dividend Per Share | 450.00 |
Dividend Yield | 3.32% |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | 23.75% |
Buyback Yield | 0.26% |
Shareholder Yield | 3.57% |
Earnings Yield | 13.98% |
FCF Yield | 18.97% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Cell Biotech has an Altman Z-Score of 10.05.
Altman Z-Score | 10.05 |
Piotroski F-Score | n/a |